Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

Nanjing Medical University

Status and phase

Unknown

Phase 2

Conditions

HER2-negative Breast Cancer

Treatments

Drug: Anlotinib hydrochloride

Drug: Eribulin Mesylate

Study type

Interventional

Funder types

Other

Identifiers

NCT04624711

EAGER-001

Details and patient eligibility

About

This is a multicenter, phase II, open-label, single-arm investigator initiated trial to evaluate the efficacy and safety of eribulin mesylate combined with anlotinib in metastatic HER2 negative breast cancer patients.

Full description

Breast cancer is the most frequent malignancy in women worldwide. Treatments on metastatic HER2 negative breast cancer are still under exploration. Therefore, it is imperative to find a novel therapy to treat these patients.

This study explores the efficacy and safety of eribulin mesylate combined with anlotinib in metastatic HER2 negative breast cancer patients. The primary objective is to evaluate the progression free survival (PFS). The secondary objective is to evaluate the safety of the combination of eribulin and anlotinib.

Enrollment

40 estimated patients

Sex

Female

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The patient volunteers and signs an informed consent form;
Age ≥18 years old, female;
The patient was diagnosed as HER2 negative breast cancer by histopathology ( HER2 negative (IHC-/+ or IHC++ but FISH/CISH- )), and there is at least 1 measurable lesion of metastasis according to RECIST 1.1;
All patients have previously underwent chemotherapy containing anthracyclines and taxanes, and received ≥1 line chemotherapy for metastatic breast cancer;
Patients with hormone receptor positive (ER positive (IHC ER positive percentage ≥1%), PR positive (IHC PR positive percentage ≥1%)) have underwent ≥1 line endocrine therapy;
Physical condition ECOG PS: 0-1;
Laboratory tests meet the following criteria:
1. Bone marrow function: absolute count of blood neutrophils (ANC) ≥1.5×109/L; platelet (PLT)≥100×109/L; hemoglobin (HB)≥90g/L;
2. Liver function: serum total bilirubin (STB), combined bilirubin (CB) ≤ upper limit of normal (ULN) *1.5; alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ULN*2.5;
3. Renal function: serum creatinine (Cr) ≤ ULN; endogenous creatinine clearance (Ccr) ≥ 60 ml / min (calculated using the Cockcroft-Gault formula).

Exclusion criteria

Previous breast cancer history (except for ipsilateral DCIS that only received local treatment ≥5 years ago), malignant tumors of other histological origins (except for non-melanoma skin cancer or cervical carcinoma in situ) unless the patient's tumor had been completely alleviated and had not received treatment for at least 5 years before the enrollment date;
Major surgery within 4 weeks prior to enrollment, or surgical wounds have not healed;
Embolization and bleeding occurred within 4 weeks before enrollment;
Severe cardiovascular disease, including hypertension (BP≥160/95mmHg) uncontrolled by medical treatment, unstable angina, history of myocardial infarction in the past 6 months, congestive heart failure>NYHA II, severe heart rhythm Abnormalities and pericardial effusions;
Severe infection requires intravenous antibiotic, antifungal or antiviral treatment;
Other clinical trials of drugs were used in the first four weeks of the first medication;
Subjects with treatment history of eribulin or anti-angiogenesis drugs;
Suffering from mental illness, poor compliance;
Researchers believe that it is not suitable for inclusion.